Skip to content

Vitamin D Influence on Oocyte Donation

Impact of Vitamin D Levels on Ovarian Reserve and Ovarian Response to Controlled Stimulation in Egg Donors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02341365
Enrollment
269
Registered
2015-01-19
Start date
2013-06-30
Completion date
2015-01-31
Last updated
2015-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorder of Phosphate, Calcium and Vitamin D Metabolism, Female Infertility Due to Diminished Ovarian Reserve, Hormonal Requirement, Reproductive Disorder

Keywords

Egg donation, vitaminD, ovarian reserve, ovarian stimulation

Brief summary

Objective: To investigate the correlation between total and bioavailable serum 25-OH vitamin D, ovarian reserve and ovarian response to controlled stimulation in egg donors.

Detailed description

Design: Retrospective study. Setting: University affiliated private IVF center. Intervention: Serum analysis of vitamin D, bioavailable vitamin D, antimullerian hormone (AMH), antral follicular count (AFC), reproductive outcome of oocytes recipients Main outcome measure: AMH, AFC, number of oocytes retrieved and number of mature oocytes, pregnancy and implantation rate of donated oocytes'recipients.

Interventions

OTHERvitamin D,AMH, AFC, reproductive outcome egg recipients

observational study of 269 donnors

Sponsors

IVI Madrid
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 34 Years
Healthy volunteers
No

Inclusion criteria

* Caucasian race, * between 18 and 34 years of age, * all donors had normal menstrual cycles of 26-34 days, * normal weight range (BMI 18- 25 Kg/m2), * normal uterus and ovaries on transvaginal ultrasound (no signs of polycystic ovarian syndrome), and * an antral follicle count (AFC) \>10, * normal karyotype

Exclusion criteria

* current or past exposure to radiation or hazardous chemical substances, * history of drug use, * family history of hereditary chromosomal diseases, * sexually transmitted diseases

Design outcomes

Primary

MeasureTime frame
Numbers of oocytes retrieved2 months

Secondary

MeasureTime frame
implantation rate2 months
pregnancy rate2 months
AFC2 months
number of mature oocytes2 months
AMH2 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026